VeraTag™ assays can provide valuable information for choosing the right
drug for the right patient at the right time.
EGFR/HER Commercial Assay Panel
We are curently developing our first commercial VeraTag assay in oncology,
a test panel measuring activated epidermal growth factor receptor (EGFR) and other
HER receptor family members that are directly targeted by approved cancer therapies.
The test panel will potentially enable healthcare providers to identify the
appropriate course of treatment for cancers that have a particular molecular
profile. We also intend to develop VeraTag assays that measure other proteins
and signaling pathways that are key drivers of proliferation and survival in
To optimally match a treatment that will be effective in killing or controlling
cancer cells to an individual patient, there is a need for predictive tests that
are able to detect the specific cellular processes active in driving the growth
of an individual patient's cancer cells. The healthcare provider will then
identify and prescribe a drug that can interfere with that particular process.
VeraTag assays can be configured to measure multiple types of protein complexes,
helping drug developers and clinicians to understand the different biological
processes associated with different categories of molecularly defined cancers and
each patient's individual tumor. By utilizing VeraTag assays, researchers and oncologists
can enhance preclinical development of targeted therapies, improve clinical trial
design, enrich the clinical trial population for likely responders, clarify the choice of
cancer therapy, optimize patient outcomes by helping redefine the standard of care,
and ultimately make the promise of individualized oncology treatment a reality.
Click here to read more about targeted cancer therapeutics.
Click here to enlarge image.
Click here to read more about patient selection testing for targeted therapies.